专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20070004788A1 Nitrosated and nitrosylated H2 receptor antagonist compounds, compositions and methods of use 失效
公开(公告)号：US20070004788A1
公开(公告)日：2007-01-04
申请号：US11518231
申请日：2006-09-11
申请人： David Garvey , L. Letts , Chia-En Lin , Tiansheng Wang
发明人： David Garvey , L. Letts , Chia-En Lin , Tiansheng Wang
IPC分类号： A61K31/426
CPC分类号： C07D233/54 , C07D233/64 , C07D277/48 , C07D295/092 , C07D295/096
摘要： The invention describes novel nitrosated and/or nitrosylated H2 receptor antagonist compounds, and novel compositions comprising at least one H2 receptor antagonist compound that is optionally substituted with at least one NO and/or NO2 group, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase and/or at least one nonsteroidal antiinflammatory drug, antacid, bismuth-containing reagent or anti-viral agent. The invention also describes methods for treating and/or preventing gastrointestinal disorders; improving gastroprotective properties of H2 receptor antagonists; decreasing the recurrence of ulcers; facilitating ulcer healing; preventing and/or treating inflammations and microbial infections, ophthalmic diseases and disorders, multiple sclerosis, and viral infections; and decreasing or reducing the gastrointestinal toxicity associated with the use of nonsteroidal antiinflammatory compounds.

2. 发明申请

US20050250758A1 Nitrosated and nitrosylated H2 receptor antagonist compounds, compositions and methods of use 失效
标题翻译：亚硝化和亚硝基化H 2受体拮抗剂化合物，组合物和使用方法
公开(公告)号：US20050250758A1
公开(公告)日：2005-11-10
申请号：US11180790
申请日：2005-07-14
申请人： David Garvey , L. Letts , Chia-En Lin , Tiansheng Wang
发明人： David Garvey , L. Letts , Chia-En Lin , Tiansheng Wang
IPC分类号： C07D295/08 , A61K31/198 , A61K31/222 , A61K31/29 , A61K31/341 , A61K31/397 , A61K31/40 , A61K31/401 , A61K31/4164 , A61K31/426 , A61K31/445 , A61K31/4453 , A61K31/55 , A61K45/06 , A61P1/04 , A61P17/00 , A61P27/02 , A61P27/06 , A61P27/16 , A61P29/00 , A61P31/00 , A61P31/04 , A61P31/18 , C07D233/54 , C07D233/64 , C07D277/28 , C07D277/48 , C07D277/52 , C07D295/096 , C07D307/52
CPC分类号： C07D233/54 , C07D233/64 , C07D277/48 , C07D295/092 , C07D295/096
摘要： The invention describes novel nitrosated and/or nitrosylated H2 receptor antagonist compounds, and novel compositions comprising at least one H2 receptor antagonist compound that is optionally substituted with at least one NO and/or NO2 group, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase and/or at least one nonsteroidal antiinflammatory drug, antacid, bismuth-containing reagent or anti-viral agent. The invention also describes methods for treating and/or preventing gastrointestinal disorders; improving gastroprotective properties of H2 receptor antagonists; decreasing the recurrence of ulcers; facilitating ulcer healing; preventing and/or treating inflammations and microbial infections, ophthalmic diseases and disorders, multiple sclerosis, and viral infections; and decreasing or reducing the gastrointestinal toxicity associated with the use of nonsteroidal antiinflammatory compounds.
摘要翻译：本发明描述了新的亚硝化和/或亚硝基化的H 2 O 2受体拮抗剂化合物，以及包含至少一种H 2受体拮抗剂化合物的新组合物，其任选被至少一个NO 和/或NO 2个基团，以及任选地，至少一种捐赠，转移或释放一氧化氮的化合物，刺激一氧化氮的内源性合成，提高内源性内皮水平的内源性松弛因子，或者是一氧化氮合酶的底物和/或至少一种非甾体抗炎药，抗酸剂，含铋试剂或抗病毒剂。本发明还描述了治疗和/或预防胃肠道疾病的方法; 改善H 2受体拮抗剂的胃保护性质; 减少溃疡复发; 促进溃疡愈合; 预防和/或治疗炎症和微生物感染，眼科疾病和病症，多发性硬化和病毒感染; 并减少或减少与使用非甾体抗炎化合物相关的胃肠道毒性。

3. 发明申请

US20050059655A1 Nitrosated and nitrosylated diuretic compounds, compositions and methods of use 失效
标题翻译：硝化和亚硝化利尿剂，组合物和使用方法
公开(公告)号：US20050059655A1
公开(公告)日：2005-03-17
申请号：US10921936
申请日：2004-08-20
申请人： David Garvey , L. Letts , Manuel Worcel , Richard Earl , Maiko Ezawa , Xinqin Fang , Subhash Khanapure , Chia-En Lin , Ramani Ranatunga , Cheri Stevenson
发明人： David Garvey , L. Letts , Manuel Worcel , Richard Earl , Maiko Ezawa , Xinqin Fang , Subhash Khanapure , Chia-En Lin , Ramani Ranatunga , Cheri Stevenson
IPC分类号： A61K20060101 , A61K31/4523 , A61K31/517 , A61K31/5415 , A61K31/549 , C07D211/00 , C07D285/22 , C07D295/00 , C07D307/00 , C07D417/12 , C07D417/14
CPC分类号： C07D403/10 , C07C205/40 , C07D233/68 , C07D235/18 , C07D257/04 , C07D307/52 , C07D401/12 , C07D401/14 , C07D405/06 , C07D405/12 , C07D405/14 , C07D409/04 , C07D409/06 , C07D409/14 , C07D413/10 , C07D471/04 , C07D487/04 , C07D495/04 , C07D498/04
摘要： The invention describes novel nitrosated and/or nitrosylated diuretic compounds or pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated and/or nitrosylated diuretic compound, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides novel compositions and kits comprising at least one diuretic compound of the invention, that is optionally nitrosated and/or nitrosylated, and, optionally, at least one nitric oxide donor compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating conditions resulting from excessive water and/or electrolyte retention; (b) treating cardiovascular diseases; (c) treating renovascular diseases; (d) treating diabetes; (e) treating diseases resulting from oxidative stress; (f) treating endothelial dysfunctions; (g) treating diseases caused by endothelial dysfunctions; (h) treating cirrhosis; (j) treating pre-eclampsia; (k) treating osteoporosis; and (l) treating nephropathy.
摘要翻译：本发明描述了新的亚硝化和/或亚硝基化的利尿剂或其药学上可接受的盐，以及包含至少一种亚硝化和/或亚硝基化的利尿剂化合物和任选的至少一种一氧化氮供体和/或至少一种治疗剂。本发明还提供了包含至少一种本发明的利尿剂化合物，其任选被亚硝化和/或亚硝基化的新组合物和试剂盒，以及任选的至少一种一氧化氮供体化合物和/或至少一种治疗剂。本发明还提供了（a）处理由过量水和/或电解质滞留导致的条件的方法; （二）治疗心血管疾病; （c）治疗血管性疾病; （d）治疗糖尿病; （e）治疗由氧化应激引起的疾病; （f）治疗内皮功能障碍; （g）治疗由内皮功能障碍引起的疾病; （h）治疗肝硬化; （j）治疗先兆子痫; （k）治疗骨质疏松症; 和（l）治疗肾病。

4. 发明申请

US20060189603A1 Nitric oxide enhancing diuretic compounds, compositions and methods of use 失效
标题翻译：一氧化氮增强利尿剂，组合物和使用方法
公开(公告)号：US20060189603A1
公开(公告)日：2006-08-24
申请号：US11360599
申请日：2006-02-24
申请人： David Garvey , L. Letts , Richard Earl , Maiko Ezawa , Xinqin Fang , Ricky Gaston , Subhash Khanapure , Chia-En Lin , Ramani Ranatunge , Cheri Stevenson , Shiow-Jyi Wey
发明人： David Garvey , L. Letts , Richard Earl , Maiko Ezawa , Xinqin Fang , Ricky Gaston , Subhash Khanapure , Chia-En Lin , Ramani Ranatunge , Cheri Stevenson , Shiow-Jyi Wey
IPC分类号： A61K31/549 , C07D417/02
CPC分类号： C07D285/30 , C07D285/28 , C07D285/32 , C07D417/04 , C07D417/06 , C07D513/10
摘要： The invention describes novel compositions and kits comprising at least one nitric oxide enhancing diuretic compound, or pharmaceutically acceptable salts thereof, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating conditions resulting from excessive water and/or electrolyte retention; (b) treating cardiovascular diseases; (c) treating renovascular diseases; (d) treating diabetes; (e) treating diseases resulting from oxidative stress; (f) treating endothelial dysfunctions; (g) treating diseases caused by endothelial dysfunctions; (h) treating cirrhosis; (j) treating pre-eclampsia; (k) treating osteoporosis; (l) treating nephropathy; (m) treating peripheral vascular diseases; (n) treating portal hypertension; (o) treating central nervous system disorders; (p) treating metabolic syndrome; (q) treating sexual dysfunctions; and (r) hyperlipidemia. The nitric oxide enhancing diuretic compounds comprise at least one nitric oxide enhancing group linked to the diuretic compound through one or more sites such as carbon, oxygen and/or nitrogen via a bond or moiety that cannot be hydrolyzed.
摘要翻译：本发明描述了包含至少一种一氧化氮增强利尿剂或其药学上可接受的盐，和任选的至少一种一氧化氮增强化合物和/或至少一种治疗剂的新型组合物和试剂盒。本发明还提供了（a）处理由过量水和/或电解质滞留导致的条件的方法; （二）治疗心血管疾病; （c）治疗血管性疾病; （d）治疗糖尿病; （e）治疗由氧化应激引起的疾病; （f）治疗内皮功能障碍; （g）治疗由内皮功能障碍引起的疾病; （h）治疗肝硬化; （j）治疗先兆子痫; （k）治疗骨质疏松症; （l）治疗肾病; （m）治疗外周血管疾病; （n）治疗门静脉高压; （o）治疗中枢神经系统疾病; （p）治疗代谢综合征; （q）治疗性功能障碍; 和（r）高脂血症。一氧化氮增强利尿化合物包含通过一个或多个位点如碳，氧和/或氮通过不能水解的键或部分与利尿剂化合物连接的至少一个一氧化氮增强基团。

5. 发明授权

US07256205B2 Nitrosated and nitrosylated H2 receptor antagonist compounds, compositions and methods of use 失效
标题翻译：亚硝化和亚硝基化H 2受体拮抗剂化合物，组合物和使用方法
公开(公告)号：US07256205B2
公开(公告)日：2007-08-14
申请号：US11518231
申请日：2006-09-11
申请人： David S. Garvey , L. Gordon Letts , Chia-En Lin , Tiansheng Wang
发明人： David S. Garvey , L. Gordon Letts , Chia-En Lin , Tiansheng Wang
IPC分类号： C07D277/42 , A61K31/426
CPC分类号： C07D233/54 , C07D233/64 , C07D277/48 , C07D295/092 , C07D295/096
摘要： The invention describes novel nitrosated and/or nitrosylated H2 receptor antagonist compounds, and novel compositions comprising at least one H2 receptor antagonist compound that is optionally substituted with at least one NO and/or NO2 group, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase and/or at least one nonsteroidal antiinflammatory drug, antacid, bismuth-containing reagent or anti-viral agent. The invention also describes methods for treating and/or preventing gastrointestinal disorders; improving gastroprotective properties of H2 receptor antagonists; decreasing the recurrence of ulcers; facilitating ulcer healing; preventing and/or treating inflammations and microbial infections, ophthalmic diseases and disorders, multiple sclerosis, and viral infections; and decreasing or reducing the gastrointestinal toxicity associated with the use of nonsteroidal antiinflammatory compounds.
摘要翻译：本发明描述了新的亚硝化和/或亚硝基化的H 2 O 2受体拮抗剂化合物，以及包含至少一种H 2受体拮抗剂化合物的新组合物，其任选被至少一个NO 和/或NO 2个基团，以及任选地，至少一种捐赠，转移或释放一氧化氮的化合物，刺激一氧化氮的内源性合成，提高内源性内皮水平的内源性松弛因子，或者是一氧化氮合酶的底物和/或至少一种非甾体抗炎药，抗酸剂，含铋试剂或抗病毒剂。本发明还描述了治疗和/或预防胃肠道疾病的方法; 改善H 2受体拮抗剂的胃保护性质; 减少溃疡复发; 促进溃疡愈合; 预防和/或治疗炎症和微生物感染，眼科疾病和病症，多发性硬化和病毒感染; 并减少或减少与使用非甾体抗炎化合物相关的胃肠道毒性。

6. 发明授权

US06936627B2 Nitrosated and nitrosylated H2 receptor antagonist compounds, compositions and methods of use 失效
公开(公告)号：US06936627B2
公开(公告)日：2005-08-30
申请号：US10282071
申请日：2002-10-29
申请人： David S. Garvey , L. Gordon Letts , Chia-En Lin , Tiansheng Wang
发明人： David S. Garvey , L. Gordon Letts , Chia-En Lin , Tiansheng Wang
IPC分类号： C07D295/08 , A61K31/198 , A61K31/222 , A61K31/29 , A61K31/341 , A61K31/397 , A61K31/40 , A61K31/401 , A61K31/4164 , A61K31/426 , A61K31/445 , A61K31/4453 , A61K31/55 , A61K45/06 , A61P1/04 , A61P17/00 , A61P27/02 , A61P27/06 , A61P27/16 , A61P29/00 , A61P31/00 , A61P31/04 , A61P31/18 , C07D233/54 , C07D233/64 , C07D277/28 , C07D277/48 , C07D277/52 , C07D295/096 , C07D307/52 , C07D233/56
CPC分类号： C07D233/54 , C07D233/64 , C07D277/48 , C07D295/092 , C07D295/096
摘要： The invention describes novel nitrosated and/or nitrosylated H2 receptor antagonist compounds, and novel compositions comprising at least one H2 receptor antagonist compound that is optionally substituted with at least one NO and/or NO2 group, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase and/or at least one nonsteroidal antiinflammatory drug, antacid, bismuth-containing reagent or anti-viral agent. The invention also describes methods for treating and/or preventing gastrointestinal disorders; improving gastroprotective properties of H2 receptor antagonists; decreasing the recurrence of ulcers; facilitating ulcer healing; preventing and/or treating inflammations and microbial infections, ophthalmic diseases and disorders, multiple sclerosis, and viral infections; and decreasing or reducing the gastrointestinal toxicity associated with the use of nonsteroidal antiinflammatory compounds.

7. 发明授权

US06656966B2 Nitrosated and nitrosylated taxanes, compositions and methods of use 失效
公开(公告)号：US06656966B2
公开(公告)日：2003-12-02
申请号：US09886494
申请日：2001-06-22
申请人： David S. Garvey , L. Gordon Letts , Chia-En Lin , Stewart K. Richardson , Tiansheng Wang
发明人： David S. Garvey , L. Gordon Letts , Chia-En Lin , Stewart K. Richardson , Tiansheng Wang
IPC分类号： A61K31337
CPC分类号： C07D409/12 , A61K31/335 , A61K45/06 , A61K47/54 , A61K47/55 , A61K47/555 , B82Y5/00 , C07D305/14 , Y10S977/775 , Y10S977/907 , Y10S977/915 , Y10S977/926 , A61K2300/00
摘要： The present invention describes novel nitrosated and/or nitrosylated taxanes, and novel compositions comprising at least one nitrosated and/or nitrosylated taxane, and, optionally, at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The present invention also provides novel compositions comprising at least one taxane and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The compounds and compositions of the present invention can also be bound to a matrix. The present invention also provides methods for treating or preventing cardiovascular diseases and disorders, autoimmune diseases, pathological conditions resulting from abnormal cell proliferation, polycystic kidney disease, inflammatory disease, preserving organs and/or tissues or to inhibit wound contraction, particularly the prophylactic and/or therapeutic treatment of restenosis, by administering nitrosated and/or nitrosylated taxane or parent taxanes in combination with nitric oxide donors that are capable of releasing nitric oxide or indirectly delivering or transferring nitric oxide to targeted sites under physiological conditions.

8. 发明授权

US07129251B2 Nitrosated and nitrosylated H2 receptor antagonist compounds, compositions and methods of use 失效
标题翻译：亚硝化和亚硝基化H 2受体拮抗剂化合物，组合物和使用方法
公开(公告)号：US07129251B2
公开(公告)日：2006-10-31
申请号：US11180790
申请日：2005-07-14
申请人： David S. Garvey , L. Gordon Letts , Chia-En Lin , Tiansheng Wang
发明人： David S. Garvey , L. Gordon Letts , Chia-En Lin , Tiansheng Wang
IPC分类号： C07D295/14 , A61K31/445 , A61P1/04
CPC分类号： C07D233/54 , C07D233/64 , C07D277/48 , C07D295/092 , C07D295/096
摘要： The invention describes novel nitrosated and/or nitrosylated H2 receptor antagonist compounds, and novel compositions comprising at least one H2 receptor antagonist compound that is optionally substituted with at least one NO and/or NO2 group, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase and/or at least one nonsteroidal antiinflammatory drug, antacid, bismuth-containing reagent or anti-viral agent. The invention also describes methods for treating and/or preventing gastrointestinal disorders; improving gastroprotective properties of H2 receptor antagonists; decreasing the recurrence of ulcers; facilitating ulcer healing; preventing and/or treating inflammations and microbial infections, ophthalmic diseases and disorders, multiple sclerosis, and viral infections; and decreasing or reducing the gastrointestinal toxicity associated with the use of nonsteroidal antiinflammatory compounds.
摘要翻译：本发明描述了新的亚硝化和/或亚硝基化的H 2 O 2受体拮抗剂化合物，以及包含至少一种H 2受体拮抗剂化合物的新组合物，其任选被至少一个NO 和/或NO 2个基团，以及任选地，至少一种捐赠，转移或释放一氧化氮的化合物，刺激一氧化氮的内源性合成，提高内源性内皮水平的内源性松弛因子，或者是一氧化氮合酶的底物和/或至少一种非甾体抗炎药，抗酸剂，含铋试剂或抗病毒剂。本发明还描述了治疗和/或预防胃肠道疾病的方法; 改善H 2受体拮抗剂的胃保护性质; 减少溃疡复发; 促进溃疡愈合; 预防和/或治疗炎症和微生物感染，眼科疾病和病症，多发性硬化和病毒感染; 并减少或减少与使用非甾体抗炎化合物相关的胃肠道毒性。

9. 发明授权

US06869973B2 Nitrosated and nitrosylated taxanes, compositions and methods of use 失效
标题翻译：硝化和亚硝化紫杉烷，组合物和使用方法
公开(公告)号：US06869973B2
公开(公告)日：2005-03-22
申请号：US10682923
申请日：2003-10-14
申请人： David S. Garvey , L. Gordon Letts , Chia-En Lin , Stewart K. Richardson , Tiansheng Wang
发明人： David S. Garvey , L. Gordon Letts , Chia-En Lin , Stewart K. Richardson , Tiansheng Wang
IPC分类号： A61F2/84 , A61K31/145 , A61K31/15 , A61K31/335 , A61K31/337 , A61K35/14 , A61K45/00 , A61K45/06 , A61K47/30 , A61K47/32 , A61K47/34 , A61K47/48 , A61L29/00 , A61L31/00 , A61P1/04 , A61P7/02 , A61P7/04 , A61P7/10 , A61P9/00 , A61P9/10 , A61P9/12 , A61P9/14 , A61P11/00 , A61P11/02 , A61P13/12 , A61P17/00 , A61P17/02 , A61P25/28 , A61P27/02 , A61P27/16 , A61P29/00 , A61P31/06 , A61P35/00 , A61P35/02 , A61P37/02 , A61P41/00 , A61P43/00 , C07D305/14 , C07D409/12
CPC分类号： C07D409/12 , A61K31/335 , A61K45/06 , A61K47/54 , A61K47/55 , A61K47/555 , B82Y5/00 , C07D305/14 , Y10S977/775 , Y10S977/907 , Y10S977/915 , Y10S977/926 , A61K2300/00
摘要： The present invention describes novel nitrosated and/or nitrosylated taxanes, and novel compositions comprising at least one nitrosated and/or nitrosylated taxane, and, optionally, at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The present invention also provides novel compositions comprising at least one taxane and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The compounds and compositions of the present invention can also be bound to a matrix. The present invention also provides methods for treating or preventing cardiovascular diseases and disorders, autoimmune diseases, pathological conditions resulting from abnormal cell proliferation, polycystic kidney disease, inflammatory disease, preserving organs and/or tissues or to inhibit wound contraction, particularly the prophylactic and/or therapeutic treatment of restenosis, by administering nitrosated and/or nitrosylated taxane or parent taxanes in combination with nitric oxide donors that are capable of releasing nitric oxide or indirectly delivering or transferring nitric oxide to targeted sites under physiological conditions.
摘要翻译：本发明描述了新的亚硝化和/或亚硝基化的紫杉烷类，以及包含至少一种亚硝化和/或亚硝基化的紫杉烷和任选的至少一种捐赠，转移或释放一氧化氮的化合物的新型组合物，提高内源性内源水平的内皮衍生舒张因子，刺激一氧化氮的内源性合成或者是一氧化氮合酶和/或至少一种治疗剂的底物。本发明还提供了包含至少一种紫杉烷和至少一种捐赠，转移或释放一氧化氮的化合物的新型组合物，提高内源性内皮衍生的松弛因子水平，刺激一氧化氮的内源性合成或者是一氧化氮合酶的底物和/或至少一种治疗剂。本发明的化合物和组合物也可以与基质结合。本发明还提供治疗或预防心血管疾病和病症，自身免疫性疾病，由异常细胞增殖引起的病理状况，多囊肾病，炎性疾病，保存器官和/或组织或抑制伤口收缩的方法，特别是预防和/ 或治疗性再狭窄，通过将硝基化和/或亚硝基化的紫杉烷或母体紫杉烷与能够释放一氧化氮或间接地将一氧化氮递送或转移到生理条件下的靶位点的一氧化氮供体组合。

10. 发明申请

US20060009431A1 Nitrosated and nitrosylated compounds, compositions and methods use 审中-公开
标题翻译：亚硝化和亚硝化化合物，组合物和方法用途
公开(公告)号：US20060009431A1
公开(公告)日：2006-01-12
申请号：US11221901
申请日：2005-09-09
申请人： Richard Earl , David Garvey , Ricky Gaston , Chia-En Lin , Ramani Ranatunge , Stewart Richardson , Cheri Stevenson
发明人： Richard Earl , David Garvey , Ricky Gaston , Chia-En Lin , Ramani Ranatunge , Stewart Richardson , Cheri Stevenson
IPC分类号： A61K31/56 , A61K31/21
CPC分类号： C07J17/00 , C07J1/00 , C07J31/006 , C07J41/0044 , C07J43/00 , C07J43/003
摘要： The invention describes novel nitrosated and/or nitrosylated compounds of the invention, and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated and/or nitrosylated compound of the invention, and, optionally, at least one nitric oxide donor compound and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one compound of the invention, that is optionally nitrosated and/or nitrosylated, and at least one nitric oxide donor compound and/or at least one therapeutic agent. The compounds and compositions of the invention can also be bound to a matrix. The invention also provides methods for treating cardiovascular diseases, for inhibiting platelet aggregation and platelet adhesion caused by the exposure of blood to a medical device, for treating pathological conditions resulting from abnormal cell proliferation; transplantation rejections, autoimmune, inflammatory, proliferative, hyperproliferative or vascular diseases; for reducing scar tissue or for inhibiting wound contraction, particularly the prophylactic and/or therapeutic treatment of restenosis by administering at least one compound of the invention that is optionally nitrosated and/or nitrosylated, in combination with nitric oxide donors that are capable of releasing nitric oxide or indirectly delivering or transferring nitric oxide to targeted sites under physiological conditions. The compounds of the invention are preferably estradiol compounds, troglitazone compounds, tranilast compounds, retinoic acid compounds, resveratol compounds, myophenolic acid compounds, acid compounds, anthracenone compounds and trapidil compounds.
摘要翻译：本发明描述了本发明的新型亚硝化和/或亚硝基化化合物及其药学上可接受的盐，以及包含至少一种本发明的亚硝基化和/或亚硝化化合物和任选的至少一种一氧化氮供体化合物和/ 或至少一种治疗剂。本发明还提供了包含至少一种本发明的化合物，其任选被亚硝化和/或亚硝基化的新化合物，以及至少一种一氧化氮供体化合物和/或至少一种治疗剂。本发明的化合物和组合物也可以结合到基质上。本发明还提供了治疗心血管疾病的方法，用于抑制由血液暴露于医疗器械引起的血小板聚集和血小板粘附，用于治疗由异常细胞增殖引起的病理状况; 移植排斥，自身免疫，炎症，增殖，过度增生或血管疾病; 用于减少瘢痕组织或抑制伤口收缩，特别是预防和/或治疗再狭窄的方法，通过给予至少一种任选地亚硝化和/或亚硝基化的本发明化合物与能够释放硝酸的一氧化氮供体组合在生理条件下氧化或间接地将一氧化氮递送或转移到靶位点。本发明的化合物优选为雌二醇化合物，曲格列酮化合物，曲尼司特化合物，视黄酸化合物，白藜芦醇化合物，肌醇酸化合物，酸化合物，蒽酮化合物和捕获剂化合物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式